Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Freshly Funded ImCheck Goes After Gamma Delta T-Cells

ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.

ImmunoOncology Companies

Novartis Enters ‘Transformational’ Cloud Computing Pact With Amazon

Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.

Deals Manufacturing

Macrophage Pharma Seeks Funding To Take Novel Cancer Therapy Forward

Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.  

Commercial Companies

Verona Foresees FDA End-Of-Phase II COPD Meeting

Verona CEO tells Scrip Phase III COPD studies for its lead asset will start next year, take up to two years to complete, leading to commercial launch “probably in 2024.”

Companies Strategy

Targeting Liver Tumors: Ascelia CEO Expects 2022 Mangoral Launch

The CEO of Ascelia Pharma is confident of a successful pivotal trial for its non-gadolinium imaging agent for the detection of liver tumors that could benefit kidney disease patients. 

Commercial Companies

AC Immune CEO Outlines ‘Roadmap’ For Fighting Alzheimer’s

AC Immune’s CEO tells Scrip that treating earlier, targeting Tau, and focusing on more homogeneous populations will be needed to successfully fight Alzheimer’s Disease.

Companies Strategy
See All
UsernamePublicRestriction

Register